相关实验视频

Updated: Jun 9, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

针对外围T细胞淋巴瘤的基于抗体的治疗方法

Nazila Shafagati¹, Suman Paul¹, Sima Rozati¹

¹The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

|October 26, 2024

概括

基于抗体的疗法对T细胞淋巴瘤有希望,T细胞淋巴瘤是癌症治疗中具有挑战性的领域. 本综述涵盖单克隆抗体,双特异性抗体,CAR-T疗法以及对外围T细胞淋巴瘤 (PTCL) 的抗体-药物结合体.

科学领域:

免疫治疗是一种免疫疗法.
在瘤学瘤学.
血液学血液学血液学

背景情况:

虽然B细胞淋巴瘤治疗已经通过抗体疗法取得了进展,但T细胞淋巴瘤 (PTCL) 面临着目标限制和异质性等挑战.
对PTCL的有效选择有限,需要新的治疗策略.

研究的目的:

审查目前和新兴的基于抗体的免疫治疗策略,用于外围T细胞淋巴瘤 (PTCL).
在PTCL治疗中讨论单克隆抗体 (mAbs),双特异性抗体 (BsAs),仿真抗原受体T细胞疗法 (CAR-T) 和抗体-药物联合体 (ADC).

主要方法:

在PTCL治疗中基于抗体的策略的文献综述.
分析T细胞生物学和新目标识别方面的进展.
探索基于抗体的四个关键治疗领域:mAbs,BsAs,CAR-T和ADCs.

主要成果:

单克隆抗体,双特异性抗体,CAR-T疗法和抗体-药物联合体代表了PTCL不断发展的治疗方式.
了解T细胞生物学方面的近期进展为治疗提供了新的点.
尽管面临挑战,这些基于抗体的方法为PTCL患者提供了新的希望.

结论:

基于抗体的策略对于推进PTCL治疗至关重要,尽管存在历史上的挑战.
对 CAR-T 和 ADCs 等新目标和治疗方法的持续研究至关重要.
未来的方向涉及克服局限性并优化这些基于抗体的PTCL治疗方法.

关键词:

通过CAR T细胞治疗治疗.在CAR-NK细胞疗法中.这是一种T细胞淋巴瘤.双特定的NK细胞疗法.双特异性的T细胞治疗.免疫疗法免疫疗法

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Humoral Immune Responses

Humoral Immune Responses